Clinical Trials Logo

Myelofibroses clinical trials

View clinical trials related to Myelofibroses.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03326310 Recruiting - Clinical trials for Chronic Myeloid Leukemia

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Start date: September 4, 2018
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided that the patient continues to derive benefit. A patient will be taken off study for reasons described in detail in section 3.12 including disease progression, unacceptable toxicity, inter-current illness, withdrawal of consent, or at the discretion of the investigator. Patients will be followed for 12 weeks after the last dose of study drug, until any study treatment related toxicities have stabilized, or until death. The total duration of the study is expected to be approximately 24 months.